Aggressive Treatment De-Escalation Feasible in HPV-Positive Oropharyngeal Cancer?

October 6, 2017
Daniel J. Ma, MD

This video highlights 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.

In this video, Daniel J. Ma, MD, of the Mayo Clinic in Rochester, Minnesota, discusses 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.

Ma presented results of the study (abstract LBA-14) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Related Content:

American Society for Radiation Oncology Annual Meeting (ASTRO)Head & Neck Cancer
First-Line Treatment With TPEx Regimen Did Not Improve OS Compared With EXTREME For HNSCC
New Biweekly Dosage of Cetuximab Receives FDA Approval for CRC, HNSCC Subtypes
Avelumab Plus Chemotherapy Fails in HNSCC Phase 3 Trial, Raises Future Research Questions